Browsing by Author "Mota, M"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Achieving K/DOQI Targets with Cinacalcet in Dialysis Patients with Secondary Hyperparathyroidism. A Portuguese Observational StudyPublication . Macário, F; Frazão, JM; Ferreira, A; Weigert, A; Mota, M; Machado, D; Birne, R; Neto, R; Baldaia Moreira, A; Soares, C; Ribeiro, S; Mendes, T; Alves, R; Gomes, H; Raposo, HSecondary hyperparathyroidism is a common complication of chronic kidney disease. The elevated serum intact parathyroid hormone, phosphorus, calcium and calcium x phosphorus product have been independently associated with an increased relative risk of mortality. The standard therapy for secondary hyperparathyroidism, including active vitamin D analogues and phosphate binders, is often insufficient to allow patients to achieve the recommended Kidney Disease Outcomes Quality Initiative targets for bone and mineral metabolism. Randomised controlled phase III clinical studies in chronic kidney disease patients with secondary hyperparathyroidism have shown that cinacalcet treatment increases the proportion of patients achieving the recommended Kidney Disease Outcomes Quality Initiative targets for intact parathyroid hormone, phosphorus, calcium and calcium x phosphorus product. Aims: This observational multicentre study aims to evaluate cinacalcet’s ability to achieve and maintain Kidney Disease Outcomes Quality Initiative targets in a population with secondary hyperparathyroidism on chronic haemodialysis in Portugal. Patients and Methods: Patients on chronic dialysis that received cinacalcet during a free sampling programme were enrolled. Retrospective and prospective monthly data were collected from 3 months before until 6 months after the beginning of cinacalcet treatment. Additional assessment included a 12 month evaluation of all parameters. Results: 140 dialysis patients with secondary hyperparathyroidism were enrolled, 60% male, mean age 57.4±14.1 years. The mean intact parathyroid hormone, calcium, phosphorus, and calcium x phosphorus product values at baseline were 751.7±498.8 pg/ml, 9.7±3.8 mg/dl, 5.5±1.5 mg/dl, and 52.7±25.3 mg2/dl2, respectively. After 6 months’ cinacalcet treatment, 26.2%, 53.6%, 59.3%, and 81.0% of the patients achieved the Kidney Disease Outcomes Quality Initiative recommended levels for intact parathyroid hormone, calcium, phosphorus, and calcium x phosphorus product, respectively. The mean dose of cinacalcet at 6 months was 57.1±29.7 mg/day. Conclusions: The use of cinacalcet in clinical practice is an effective option for the treatment of secondary hyperparathyroidism in chronic dialysis patients, allowing more patients to reach and maintain the Kidney Disease Outcomes Quality Initiative targets.
- Avaliação da Prevalência e Caracterização da Rinossinusite em Portugal - Estudo EpidemiológicoPublication . Barros, E; Monteiro, L; Prata, JB; Vieira, AS; Tomé, P; Gonçalves, P; Santos, A; Mota, M; Macedo, AObjectivos: Determinar a prevalência e caracterizar o perfil dos doentes com rinossinusite aguda e crónica, em Portugal Continental. Desenho do estudo: Estudo epidemiológico transversal. Metodos: Aplicação de um questionário a um grupo representativo de 5.116 indivíduos de ambos os sexos, entre os 14 e os 65 anos. Resultados: A prevalência total de rinossinusite foi de 13,7%(11,3% aguda e 2,4% crónica), sendo mais frequente em mulheres, nas faixas etárias dos 30 aos 39 anos e acima dos 60 anos, nas zonas de Lisboa e Vale do Tejo (LVT), Alentejo e Algarve. A prevalência de rinossinusite crónica é maior no Norte (50%), em inquiridos com idade media de 43 anos. A rinossinusite crónica é frequentemente acompanhada de outras patologias e sintomas e motiva mais consultas médicas do que a rinossinusite aguda. Conclusão: A sensibilização para a importância do diagnóstico correcto, ao mesmo tempo que se contraria a tendência da automedicação recorrente de relevância extrema na prevenção e tratamento da rinossinusite.